86 results match your criteria: "Charité University Medicine of Berlin[Affiliation]"
Int J Gynecol Cancer
December 2024
Department of Gynecology and Gynecologic Oncology, KEM, Kliniken Essen Mitte, Essen, Germany.
Objective: The aim of this study was to investigate the association of co-medication with metformin, a statin, or beta blocker with survival in patients with primary ovarian cancer.
Methods: Individual data from three phase III, randomized controlled trials (AGO-OVAR 11, AGO-OVAR 12, and AGO-OVAR 16) and one phase II trial (AGO-OVAR 15) were pooled and analyzed. Patients were classified as ever user if the specific co-medication was documented at least once during the trial, and were compared with never users as controls.
Cancers (Basel)
September 2023
Department of Radiology, Charité-University Medicine of Berlin, Campus Charité Virchow, 13353 Berlin, Germany.
Peritoneal carcinomatosis-associated malignant bowel obstruction is a common feature that merits more attention in advanced and recurrent ovarian cancer. Decompressive gastrostomy is one of the most preferred methods to palliate distressing symptoms and maintain patients' quality of life. We retrospectively identified 31 patients with ovarian cancer-associated MBO, who underwent decompressive CT fluoroscopy-guided percutaneous gastrostomy (CT-PG) between September 2015 and April 2023 at our institution.
View Article and Find Full Text PDFBull Cancer
March 2024
Division of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium.
An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the participating study groups and societies. HIPEC became a treatment option in patients with advanced colon cancer after positive results of a randomized trial comparing surgery and HIPEC versus palliative treatment alone.
View Article and Find Full Text PDFJ Oral Rehabil
January 2024
Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Objective: This paper aims to present and describe the Standardised Tool for the Assessment of Bruxism (STAB), an instrument that was developed to provide a multidimensional evaluation of bruxism status, comorbid conditions, aetiology and consequences.
Methods: The rationale for creating the tool and the road map that led to the selection of items included in the STAB has been discussed in previous publications.
Results: The tool consists of two axes, specifically dedicated to the evaluation of bruxism status and consequences (Axis A) and of bruxism risk and etiological factors and comorbid conditions (Axis B).
J Oral Rehabil
January 2024
Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Clin Exp Dent Res
February 2022
Private Practice, Berlin, Germany.
Objectives: The oral status of nursing home residents is poor. This could compromise general health. The controlled study investigated the influence of quarterly professional dental hygiene interventions on oral and general health of elderly.
View Article and Find Full Text PDFNeuroimage Clin
July 2021
Machine Learning Department, Computer Science, Technische Universität Berlin, Berlin, Germany; Neurophotonics Center, Biomedical Engineering, Boston University, Boston, USA.
Besides passive recording of brain electric or magnetic activity, also non-ionizing electromagnetic or optical radiation can be used for real-time brain imaging. Here, changes in the radiation's absorption or scattering allow for continuous in vivo assessment of regional neurometabolic and neurovascular activity. Besides magnetic resonance imaging (MRI), over the last years, also functional near-infrared spectroscopy (fNIRS) was successfully established in real-time metabolic brain imaging.
View Article and Find Full Text PDFJ Geriatr Oncol
April 2021
Charité - University Medicine of Berlin, Department of Gynecology, Center of Oncological Surgery, Berlin, Germany.
Background: Aim of this study is to evaluate the predictive ability of Fried Frailty Score for surgical outcomes in patients undergoing gynecologic cancer surgery.
Methods: This is a prospective cohort study at an academic gynecological cancer center from Oct 2015 through Jan 2017. We applied systematically numerous screening tools, geriatric questionnaires and single measurements which may provide predictions for surgical outcomes.
Anticancer Res
October 2020
Department of Gynecology with Center for Oncological Surgery, European Competence Center for Ovarian Cancer, Charité - Campus Virchow-Klinikum, University Medicine of Berlin, Berlin, Germany.
Background/aim: Angiosarcoma of primary gynecologic origin is an extremely rare and highly malignant tumor of endothelial origin with a 5-year survival rate of less than 35%. To date, only 61 cases have been described in the literature. The aim of this study was to present more cases and discuss potential therapy options.
View Article and Find Full Text PDFAm J Obstet Gynecol
October 2020
Division of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
This is the first collaborative Enhanced Recovery After Surgery Society guideline for optimal perioperative care for vulvar and vaginal surgeries. An Embase and PubMed database search of publications was performed. Studies on each topic within the Enhanced Recovery After Surgery vulvar and vaginal outline were selected, with emphasis on meta-analyses, randomized controlled trials, and prospective cohort studies.
View Article and Find Full Text PDFTarget Oncol
June 2020
Medical Oncology Department, Centre François Baclesse, Université Unicaen and GINECO, Caen, France.
The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management of the main adverse events (AEs) that may occur during rucaparib treatment. We searched PubMed and congress proceedings for safety data on oral rucaparib monotherapy (600 mg twice daily) from clinical trials involving patients with relapsed ovarian cancer.
View Article and Find Full Text PDFHemasphere
December 2018
Department of Internal Medicine III, Ludwig-Maximilians University Munich-Grosshadern, Munich, Germany.
The MabThera and Involved field Radiotherapy study investigated efficacy and safety of involved field (IF) radiotherapy in combination with the anti-CD20 antibody Rituximab for early-stage follicular lymphoma (FL) in a prospective, single-arm multicenter phase 2 design. Eighty-five stage I-II FL patients received 8 cycles of Rituximab (375 mg/m) and IF irradiation (30/40 Gy). The primary endpoint was progression-free survival (PFS) 2 years from treatment start.
View Article and Find Full Text PDFSupport Care Cancer
April 2020
European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
Background: Aim of this study was to analyze the impact of pain on quality of life and survival in recurrent OC patients.
Methods: Raw data including the QLQ-C30 questionnaire from three phase II/III trials ("Topotecan phase III," "Hector," and "TRIAS") conducted by the North-Eastern German Society of Gynecological Oncology (NOGGO) were synthesized and analyzed using logistic and Cox regression analyses.
Results: Data on pain was available for 952 patients out of 1226.
Gynecol Oncol
September 2019
European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology and Gynecological Oncology, Charité Comprehensive Cancer Center (CCCC), Charité-University Medicine of Berlin, Campus Virchow Klinikum, Augustenberger Platz 1, 13353 Berlin, Germany. Electronic address:
Objective: Low-grade epithelial ovarian cancers (EOC), constitute the minority among all epithelial cancers. Our study objective was to focus on low-grade recurrent EOC and compare the survival with high-grade disease, as well as in regard to "platinum-sensitive" and "-resistant" recurrences according to platinum-free interval.
Methods: This is an exploratory analysis within the North-Eastern German Society of Gynecological Oncology (NOGGO) database including five randomized phase II/III trials comparing different chemotherapy regimens in recurrent EOC.
Methods Mol Biol
January 2020
Institut für Biochemie, Charité-University Medicine of Berlin, CCO Virchowweg, Berlin, Germany.
Mass spectrometry (MS) is today one of the most important analytical techniques in biosciences. The development of electro spray ionization (ESI) as a gentle method, in which molecules are not destroyed, has revolutionized the analytic of peptides. MS is an ideal technique for detection and analysis of peptides generated by purified 20S proteasomes in in vitro experiments.
View Article and Find Full Text PDFSupport Care Cancer
January 2020
European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
Background: The aim of this study was to analyze the potential impact of chemotherapy-induced nausea and vomiting (CINV) on dose reductions, discontinuation of chemotherapy, and survival.
Patients And Methods: This study was designed as individual participant data meta-analysis with the original study data of three phase II/III trials that were conducted by the North-Eastern German Society of Gynecological Oncology (NOGGO) including 1213 patients with recurrent ovarian cancer. Logistic and Cox regression analyses were used to estimate odds and hazard ratios after adjusting for age, ECOG, amount of delivered cycles, amount of recurrences, and amount of comedications and study.
Anticancer Res
October 2018
European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité - University Medicine of Berlin, Berlin, Germany.
Background/aim: Chemotherapy-associated toxicity is one of the limiting factors regarding treatment efficacy, patient outcome and quality of life in this collective. Underweight or obese patients represent a major group in which the therapy seems to be more challenging. The aim of this analysis was to evaluate the impact of BMI on the toxicity in patients undergoing chemotherapy.
View Article and Find Full Text PDFJ Gynecol Oncol
November 2018
Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany.
The introduction of checkpoint inhibitors revolutionized immuno-oncology. The efficacy of traditional immunotherapeutics, like vaccines and immunostimulants was very limited due to persistent immune-escape strategies of cancer cells. Checkpoint inhibitors target these escape mechanisms and re-direct the immune system to anti-tumor toxicity.
View Article and Find Full Text PDFInt J Gynecol Cancer
October 2018
European Competence Center for Ovarian Cancer, Charité Comprehensive Cancer Center, Department of Gynecology, Charité-University Medicine of Berlin, Campus Virchow Clinic.
Objective: The aim of this study was to estimate surgical outcome and survival benefit after completion surgery.
Methods: We evaluated 164 patients with epithelial ovarian cancer who underwent incomplete primary cytoreductive surgery or rather received only staging procedures from January 2000 to December 2014 in outside institutions. Patient-related data were registered in prospective database of Tumor Bank Ovarian Cancer.
Anticancer Res
August 2018
Department of Gynaecology, Charité - University Medicine of Berlin, European Competence Centre for Ovarian Cancer, Berlin, Germany.
Background: Despite many years of clinical research and development, nausea and vomiting remain challenging toxicities related to chemotherapy. The aim of our study was to clarify the significance of non-pharmacological, patient-related risk factors for chemotherapy-induced nausea and vomiting. Furthermore, we aimed to develop a unique patient-related risk score predicting nausea and vomiting in patients with gynaecological malignancies under chemotherapy.
View Article and Find Full Text PDFPediatr Diabetes
August 2018
University of Ulm, Institute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, Ulm, Germany.
Background: A paucity of reports in the literature exists concerning the co-existence between autism spectrum disorder (ASD) and type 1 diabetes (T1D).
Objective: To compare clinical characteristics, diabetes management and metabolic control in youth with T1D and ASD (T1D-ASD) with youth without ASD (T1D-non ASD).
Methods: Using the German/Austrian diabetes patient follow-up registry, this study analyzed aggregated data from the last available year of observation for each patient with T1D, ages 1-20 with consistent data on insulin regimen and glycated hemoglobin (A1C), between January, 2005 and March, 2017.
PLoS One
January 2018
Department of Obstetrics and Gynecology, Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria.
Background: Screening for ovarian cancer (OC) in women at high risk consists of a combination of carbohydrate antigen 125 (CA125) and transvaginal ultrasound, despite their low sensitivity and specificity. This could be improved by the combination of several biomarkers, which has been shown in average risk patients but has not been investigated until now in female BRCA mutation carriers.
Methods: Using a multiplex, bead-based, immunoassay system, we analyzed the concentrations of leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, CA125 and human epididymis antigen 4 in 26 healthy wild type women, 26 healthy BRCA1 mutation carriers, 28 wildtype OC patients and 26 OC patients with BRCA1 mutation.
Arch Gynecol Obstet
January 2018
Center for Oncological Surgery, European Competence Center for Ovarian Cancer, Charité University Medicine of Berlin, Campus Virchow-Klinikum, Berlin, Germany.
Purpose: Until now there are no systematic studies about the long-term course of myoma growth. Therefore, the aims of the present study were: (1) ultrasound monitoring of the natural course of growth of uterine leiomyomas; (2) assessment of whether the growth of myomas depends on the age of the patients, the location, or the initial size (possible co-factors/predictor criteria for increase of growth); influence of oral contraceptives (OC).
Methods: Patient records (2010-May 2016) were retrospectively and systematically evaluated in regards to their growth and clinical course.
Anticancer Res
May 2017
Department of Gynecology with Center for Oncological Surgery, European Competence Center for Ovarian Cancer, Charité - Campus Virchow-Klinikum, University Medicine of Berlin, Berlin, Germany
Background: Pleomorphic rhabdomyosarcomas of the uterus, mainly occurring in postmenopausal women with leading symptoms of vaginal bleeding and abdominal pain, are very rare malignant tumors of the female genital tract. Due to the inefficiency of the adjuvant therapy, the outcome remains poor in the majority of the reported cases.
Patient And Methods: We present a case of a 73-year-old patient diagnosed with pleomorphic rhabdomyosarcoma of the uterus.
Reprod Fertil Dev
October 2017
Laboratorio de Fisiología y Farmacología de la Reproducción, Centre for Pharmacological and Botanicals Studies (CONICET - Facultad de Medicina, University of Buenos Aires), Paraguay 2155, 16th floor, Buenos Aires, Argentina.
Lysophosphatidic acid (LPA) affects several female reproductive functions through G-protein-coupled receptors. LPA contributes to embryo implantation via the lysophospholipid LPA receptor. In the present study we investigated the participation of endogenous LPA signalling through the LPA receptor in vascularisation and decidualisation, two crucial events at the maternal-fetal interface.
View Article and Find Full Text PDF